Evidence map›Paper›PMID 31818821›Full record

ArticleAntimicrobial agents and chemotherapy2020

Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle.

Eric Rhoden, Terry Fei Fan Ng, Ray Campagnoli, W Allan Nix, Jennifer Konopka-Anstadt, Rangaraj Selvarangan, Laurence Briesach, M Steven Oberste, William C Weldon

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Enterovirus A71 antivirals: Past, present, and future.Acta pharmaceutica Sinica. B · 2022
    Article
  7. Repurposing Antifungals for Host-Directed Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  8. TheInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eric RhodenDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA erhoden@cdc.gov.
Terry Fei Fan NgDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4815-8697
Ray CampagnoliDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
W Allan NixDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jennifer Konopka-AnstadtDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Rangaraj SelvaranganChildren's Mercy Hospital, Kansas City, Missouri, USA.
Laurence BriesachIHRC, Inc., Atlanta, Georgia, USA.
M Steven ObersteDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
William C WeldonDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USChildren's Mercy Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viruses in species

Indexed as

AnimalsAntifungal AgentsAntiviral AgentsEnterovirusItraconazoleParechovirusTriazolesAntifungal AgentsAntiviral AgentsItraconazoleposaconazoleTriazolesantiviralenterovirusitraconazoleparechovirusposaconazole

Identifiers

PMID31818821
PMCPMC7038243
OpenAlexW2993023884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.